Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment

BACKGROUND: Both vedolizumab and ustekinumab can be considered for the treatment of Crohn’s disease (CD) when anti‐TNF treatment fails. However, head‐to‐head trials are currently not available or planned. AIM: To compare vedolizumab and ustekinumab in Crohn´s disease patients in a prospective regist...

Descripción completa

Detalles Bibliográficos
Autores principales: Biemans, Vince B. C., van der Woude, C. Janneke, Dijkstra, Gerard, van der Meulen‐de Jong, Andrea E., Löwenberg, Mark, de Boer, Nanne K., Oldenburg, Bas, Srivastava, Nidhi, Jansen, Jeroen M., Bodelier, Alexander G. L., West, Rachel L., de Vries, Annemarie C., Haans, Jeoffrey J. L., de Jong, Dirk, Hoentjen, Frank, Pierik, Marieke J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318204/
https://www.ncbi.nlm.nih.gov/pubmed/32441396
http://dx.doi.org/10.1111/apt.15745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318204/
https://www.ncbi.nlm.nih.gov/pubmed/32441396
http://dx.doi.org/10.1111/apt.15745

Ejemplares similares